Joseph Kennedy is the executive vice president, general counsel, and secretary of strategic initiatives at Amarin, roles he has held since 2011.
Having spent more than 20 years working with life science companies, Kennedy has experience at all stages of development, from the startup phase to IPOs to product commercialization.
Before Amarin, Kennedy was the vice president and general counsel at Transcept Pharmaceuticals, where he had a key role in negotiating the company’s collaboration with Purdue Pharma and helped obtain FDA approval for the company’s lead product. He previously held the roles of chief legal officer and chief corporate counsel at Eyetech Pharmaceuticals. Kennedy led both Transcept and Eyetech through their public company transitions.
Kennedy also served as vice president and U.S. counsel for corporate business development at Elan Corporation, a biotechnology company headquartered in Dublin, Ireland. He assisted the company in acquiring technologies and managed legal issues related to collaborations. He also participated in a sale of assets, raising over $2 billion in a restructuring.
Additionally, he practiced law at Orrick, Herrington & Sutcliffe LLP.
Kennedy has been honored for his work on numerous occasions, including by Financial Times’ North American Most Innovative Lawyers Awards in 2016, on the Legal500 GC Powerlist: United States 2019, and by the president of Ireland as one of the “Irish Life Science 50,” recognizing Irish-Americans’ contributions to the life science industry.
He earned his bachelor’s degree from Fairfield University and his J.D. from New York Law School.
How do I contact Joseph T. Kennedy?
Has Joseph T. Kennedy been buying or selling shares of Amarin?
Joseph T. Kennedy has not been actively trading shares of Amarin during the last quarter. Most recently, Joseph T. Kennedy sold 54,186 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $19.52, for a transaction totalling $1,057,710.72. Learn More on Joseph T. Kennedy's trading history.
Who are Amarin's active insiders?
Are insiders buying or selling shares of Amarin?
During the last twelve months, Amarin insiders bought shares 2 times. They purchased a total of 174,426 shares worth more than $118,124.34. During the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 34,131 shares worth more than $26,963.49. The most recent insider tranaction occured on August, 2nd when CEO Aaron Berg bought 160,000 shares worth more than $102,400.00. Insiders at Amarin own 2.0% of the company.
Learn More about insider trades at Amarin. Information on this page was last updated on 8/2/2024.
